Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 nov. 2025 10h00 HE | Source: Navigator Medicines INC

Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases

Full Study Results Expected in Q1 2026Further Clinical Development of NAV-240 in Hidradenitis Suppurativa to Begin in Early 2026 SCOTCH PLAINS, NJ., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Navigator...
17 sept. 2025 01h00 HE | Source: Navigator Medicines INC

Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases

Positive safety and tolerability profile of NAV-240 in Phase 1a study support further developmentPhase 1b study fully enrolled and data expected in early 2026Further clinical development of NAV-240 to...